Ipamorelin
Research use only.
High-purity research-grade Ipamorelin
Ipamorelin is a synthetic growth hormone-releasing peptide widely studied for its selective ability to stimulate endogenous growth hormone (GH) secretion. As a highly targeted growth hormone secretagogue, Ipamorelin is commonly explored in research involving recovery, body composition, tissue repair, and anti-aging pathways. Compared to earlier GHRPs, it is noted for its relatively selective GH release profile with minimal influence on cortisol or prolactin in experimental settings.
Product overview
Ipamorelin is a pentapeptide that acts as a ghrelin receptor (GHS-R1a) agonist, triggering pulsatile growth hormone release from the pituitary gland. Research involving Ipamorelin has focused on its ability to elevate GH and IGF-1 levels in a controlled manner, supporting anabolic signaling and regenerative processes without strong activation of other endocrine pathways observed in older secretagogues.
Key research features
Supports endogenous growth hormone release: Studies indicate Ipamorelin may stimulate natural GH secretion, contributing to increased IGF-1 levels and downstream anabolic activity. This mechanism has made it a widely studied compound in recovery and anti-aging research models.
Recovery and tissue repair: Research suggests Ipamorelin may support muscle repair, connective tissue regeneration, and post-stress recovery. Experimental findings indicate potential benefits for healing processes and improved recovery following physical or metabolic stress.
Body composition and metabolic support: By influencing growth hormone pathways, Ipamorelin has been investigated for its potential role in supporting lean muscle maintenance, fat metabolism, and improved nutrient partitioning. These effects have made it a common focus in body composition research.
Sleep and regenerative processes: Ipamorelin has also been explored for its potential influence on sleep architecture, particularly deep sleep phases associated with endogenous growth hormone release and physiological recovery.
Ipamorelin Suggested Use:
Typical Dose: 100–300 mcg per administration
Route: Subcutaneous injection
Frequency: 1–3 times daily
Duration: 4–12 weeks, or as recommended by a healthcare professional